GlassScriptPhysician profile
Barry Goldman
NPI 1831139856
$42,214.97
in general payments reported to CMS, 2019-2025
31 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $159 · 2021: $315 · 2022: $1,031 · 2023: $771 · 2024: $2,215 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,130.04 |
| Education | $203.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $32,663.01 | 2019-2021 | |
| Dermira, INC. | $2,181.68 | 2019 | |
| Janssen Biotech, INC. | $1,396.55 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,084.62 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $582.96 | 2022-2025 | Dupixent |
| Genzyme Corporation | $579.38 | 2019-2025 | |
| Amgen INC. | $448.42 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $444.87 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $396.28 | 2019-2025 | |
| Galderma Laboratories, L.P. | $361.87 | 2022-2025 | Nemluvio, Aklief |
| Ucb, INC. | $256.15 | 2023-2024 | Bimzelx |
| Botanix Sb INC | $242.73 | 2025 | Sofdra |
| Almirall LLC | $238.67 | 2019 | |
| Lilly USA, LLC | $222.39 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $210.17 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $148.77 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $137.51 | 2021-2024 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $107.87 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $105.28 | 2024-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.51 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Dermavant Sciences, INC. | $51.42 | 2024 | Vtama |
| Organon LLC | $48.43 | 2025 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $36.19 | 2024 | Clear & Brilliant |
| Pfizer INC. | $33.18 | 2020-2023 | |
| Celgene Corporation | $24.58 | 2019 | |
| Journey Medical Corporation | $21.93 | 2025 | |
| Arcutis Biotherapeutics, INC. | $21.62 | 2024 | Zoryve |
| Medtronic Vascular, INC. | $19.49 | 2020 | |
| Vyne Pharmaceuticals INC. | $18.87 | 2020 | |
| Prugen, INC. Pharmaceuticals | $18.67 | 2019 | |
| Merz North America, INC. | $16.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.